Back to Journals » OncoTargets and Therapy » Volume 11

Ablation of MCM10 using CRISPR/Cas9 restrains the growth and migration of esophageal squamous cell carcinoma cells through inhibition of Akt signaling [Retraction]

Authors Yan J, Du P, Jia Y, Chang Z, Gan S, Xu X, Wang Y, Qin Y, Kan Q

Received 15 August 2018

Accepted for publication 15 August 2018

Published 21 August 2018 Volume 2018:11 Pages 5045—5046

DOI https://doi.org/10.2147/OTT.S184054


Yan J, Du P, Jia Y, Chang Z, Gan S, Xu X, Wang Y, Qin Y, Kan Q. Ablation of MCM10 using CRISPR/Cas9 restrains the growth and migration of esophageal squamous cell carcinoma cells through inhibition of Akt signaling. Onco Targets Ther. 2018;11:3323–3333.
 
At the request of the author, the Editor-in-Chief and Publisher of OncoTargets and Therapy wish to retract the published article.

After carefully checking the original record, the authors noted that the images of representative wells for wild type and Clone 1 shown in Figure 3B had been inadvertently duplicated. Upon careful review it was found there was no significant difference between the number of clones on the wild type and Clone 1 samples. In the context of only one set of data, the authors cannot conclude without doubt that ablation of MCM10 reduces the colony formation of esophageal cancer cells. The authors wish to point out that all other findings reported in the article are still valid.

The authors wish to apologize for this error.

This retraction relates to this paper

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]